AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma -
NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline. The data will be shared through multiple oral presentations and posters spanning solid tumors and blood cancer indications.
Collectively, these presentations highlight AbbVie's continued focus on attacking cancer from inside and outside the cell, supported by sustained investment in its expanding antibody‑drug conjugate (ADC) platform, including Topoisomerase I inhibitor (Top1i)–based ADCs and its T‑cell engager (TCE) portfolio.
"Our oncology pipeline is intentionally designed to address the complexity and heterogeneity of cancer biology through a diversified portfolio of differentiated therapies spanning multiple modalities," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology. "The data we are presenting at ASCO reflect the strength of this strategy, including continued momentum with our ADC programs in solid tumors and validation of immune-based approaches, such as etentamig, being investigated as a next-generation TCE in multiple myeloma. These results underscore our commitment to advancing assets with distinct scientific approaches aimed to address critical unmet patient needs."
Key findings presented include:
Data from AbbVie's Top1i ADCs Across Solid Tumors:
Further information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/.
Additional details on key presentations are available below, and the full ASCO Annual Meeting 2026 abstracts are available here.
Title
Date/Time
Session
Abstract
Number
Etentamig in patients (pts) with
relapsed/refractory multiple
myeloma (RRMM) with prior
exposure to B-cell maturation
antigen (BCMA)-targeted therapy.
Friday,
May 29
5:09-5:21
PM CDT
Oral Presentation
Oral Abstract
Session
Hematologic
Malignancies—
Plasma Cell
Dyscrasia
7508
Phase 1 basket study of
telisotuzumab adizutecan
(Temab-A, ABBV-400), a
c-Met protein-targeting antibody-
drug conjugate: Results from
patients with platinum-resistant
ovarian/primary
epithelial/fallopian tube cancer
(PROC).
Saturday,
May 30
8:42-8:48
AM CDT
Rapid Oral
Abstract Session
Gynecologic
Cancer
5514
A phase 2 randomized study
comparing telisotuzumab
adizutecan monotherapy with
standard of care in patients with
post-adjuvant circulating tumor
DNA-positive colorectal cancer.
Saturday,
May 30
9:00 AM-
12:00 PM
CDT
Poster Board:
447a
Poster Session
Gastrointestinal
Cancer—Colorectal
and Anal
TPS3688
A Phase 2 study of telisotuzumab
adizutecan (ABBV-400; Temab-A)
in patients with advanced solid
tumors harboring MET
amplification.
Saturday,
May 30
1:30-4:30
PM CDT
Poster Board:
293a
Poster Session
Developmental
Therapeutics—
Molecularly
Targeted Agents
and Tumor Biology
TPS3157
Phase 1 basket study of
telisotuzumab adizutecan (ABBV-
400, Temab-A), a c-Met protein-
targeting antibody-drug
conjugate: Results from patients
with head and neck squamous
cell carcinoma (HNSCC).
Saturday,
May 30
1:30-4:30
PM CDT
Poster Board:
484
Poster Session
Head and Neck
Cancer
6027
Telisotuzumab adizutecan
(Temab-A) plus osimertinib (osi)
as 1L treatment for
unresectable/metastatic NSCLC.
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board:
451a
Poster Session
Lung Cancer—
Non-Small Cell
Metastatic
TPS8663
Impact of MET amplification
(amp) on telisotuzumab vedotin
(Teliso-V) efficacy and safety in
2L+ non-squamous (NSQ) EGFR
wild-type (WT) NSCLC with c-Met
protein overexpression (OE).
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board: 314
Poster Session
Lung Cancer—
Non-Small Cell
Metastatic
8524
AndroMETa-Lung-713: A phase
2/3 study of telisotuzumab
adizutecan (ABBV-400, Temab-A)
vs standard of care (SOC) in
patients with epidermal growth
factor receptor (EGFR)-mutated
non-small cell lung cancer
(NSCLC).
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board:
450a
Poster Session
Lung Cancer—
Non-Small Cell
Metastatic
TPS8661
SEZanne: A phase 2 randomized,
open-label, multicenter study to
evaluate the optimal dose, safety,
and efficacy of ABBV-706 in
combination with atezolizumab
(atezo) versus standard of care
(SOC) in patients (pts) with
previously untreated extensive-
stage (ES) small cell lung cancer
(SCLC).
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board:
603a
Poster Session
Lung Cancer—Non-
Small Cell Local-
Regional/Small
Cell/Other
Thoracic Cancers
TPS8135
A phase 1, first-in-human (FIH)
study evaluating the safety,
pharmacokinetics, and efficacy of
ABBV-969 in patients with
metastatic castration-resistant
prostate cancer (mCRPC).
Sunday,
May 31
4:42-4:48
PM CDT
Rapid Oral
Abstract Session
Genitourinary
Cancer—Prostate,
Testicular,
and Penile
5014
A single-arm, phase 2 study of
neoadjuvant mirvetuximab
soravtansine and carboplatin for
FRα-expressing advanced-stage
serous epithelial ovarian, fallopian
tube, or primary peritoneal cancer
(M25-231; NCT06890338; GOG-
3115).
Monday,
June 1
9:00 AM-
12:00 PM
CDT
Poster Board:
296b
Poster Session
Gynecologic
Cancer
TPS5633
ABBV-706 as monotherapy and in
combination with budigalimab in
patients with relapsed/refractory
(R/R) small cell lung cancer (SCLC).
Monday,
June 1
3:39-3:51
PM CDT
Oral Presentation
Oral Abstract
Session
Lung Cancer—Non-
Small Cell Local-
Regional/Small
Cell/Other
Thoracic Cancers
8008
Phase 1, first-in-human (FIH)
study evaluating safety and
efficacy of ABBV-706: Results
from patients with high-grade
central nervous system (CNS)
tumors.
Monday,
June 1
1:30-4:30
PM CDT
Poster Board: 406
Poster Session
Central Nervous
System Tumors
2041
A US-based, retrospective,
observational study of biomarker
testing patterns across lines of
therapy in patients with
metastatic colorectal cancer.
N/A
Publication Only
Gastrointestinal
Cancer –
Colorectal and
Anal
e15526
Timing of biomarker testing and
associated clinical outcomes in
ovarian cancer patients: A
retrospective study.
N/A
Publication Only
Gynecologic
Cancer
e17574
Real-world (RW) characteristics
and outcomes in platinum-
resistant ovarian cancer (PROC)
patients treated with
mirvetuximab soravtansine
(MIRV) monotherapy or single-
agent chemotherapy (CTx).
N/A
Publication Only
Gynecologic
Cancer
e17606
Telisotuzumab adizutecan (Temab-A), etentamig, ABBV-969, and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
U.S. Prescribing Information for AbbVie Medicines
Please see full Prescribing Information for ELAHERE™ (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv)
Please see full Prescribing Information for EPKINLY ® (epcoritamab -bysp)
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
Contacts:
Media:
Investors:
Sourojit (Jit) Bhowmick, Ph.D.
Liz Shea
[email protected]
[email protected]
SOURCE AbbVie